Functional Analysis of GPR143 in Pulmonary Hypertension
| Project/Area Number |
15K21271
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Anesthesiology
General pharmacology
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
KOGA Motokazu 横浜市立大学, 医学部, 助教 (00637233)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 肺高血圧症 / L-DOPA / GPR143 / モノクロタリン / DOPA / 肺高血圧 |
|---|
| Outline of Final Research Achievements |
We have been working that L-DOPA, a dopamine precursor has unique physiological activity. In 2017, Masukawa reported that L-DOPA receptor candidate, GPR-143, interact with alpha adrenergic receptor and modulating its action. Therefore, we have investigated at first that L-DOPA has any interaction to vasoconstriction of pulmonary artery. As a result we found that L-DOPA also enhance phenylephrine induced vasoconstriction in pulmonary artery. Moreover, interestingly, this action is attenuated in early stage of monocrotaline-induced pulmonary hypertensive rat model. This findings may yield novel pathological and therapeutic finding in pulmonary hypertension.
|
Report
(4 results)
Research Products
(1 results)
